Iovance Sets Q2 Revenue Guidance, Amtagvi Shows Durable Efficacy in Melanoma
IOVA has more than doubled off its 52-week low of $1.68.
Summary
Iovance Biotherapeutics reaffirmed its FY2026 revenue guidance of $350-$370 million and provided new Q2 revenue guidance of $86-$88 million. This follows the initial FY2026 guidance provided in early May. The company also reported durable efficacy for its key drug Amtagvi in advanced melanoma and noted expansion to over 90 treatment centers and 1,500+ patients. These updates indicate continued operational progress and confidence in its commercialized product and pipeline.
At the time of this announcement, IOVA was trading at $4.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $1.68 to $5.63. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.